IMMU Continues Ascent, IDXG On Fire, REGN's Kevzara Disappoints In COVID-19 Trial, BLFS On Watch

Today's Daily Dose brings you news about BioLife Solutions' preliminary second-quarter revenue estimate; Immunomedics' immediate catalyst; Interpace Biosciences' stock price spike; MEI Pharma discontinuing Pracinostat trial in AML patients due to lack of efficacy and disappointing outcome from Regeneron/Sanofi's study evaluating Kevzara in COVID-19 patients.

from RTT - Biotech https://ift.tt/2YTkAaT
via IFTTT